INS and type 2 diabetes mellitus: Patients were eligible to be enrolled in the study if they were 30–75 years old, had been diagnosed with T2D and were using insulin in a total daily dose (TDD) of 0.5–1.8 U/kg, not exceeding 220 U/day.